Pupillary Response After Glaucoma Medication

NCT ID: NCT02522039

Last Updated: 2015-08-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-31

Study Completion Date

2014-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigation of the effect on the pupillary constriction by latanoprost, dorzolamide,timolol in healthy subjects. The pupillary constriction is compared to no drug.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug Effect (Glaucoma Drugs)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Latanoprost

solution, 1 drop of 50ug/ml latanoprost, was given to study eye after washout period of 1 week between drugs

Group Type EXPERIMENTAL

Latanoprost

Intervention Type DRUG

1 drop of latanoprost was given to study eye after washout period of 1 week between drugs

Timolol

solution, 1 drop of 5mg/ml timolol , was given to study eye after washout period of 1 week between drugs

Group Type EXPERIMENTAL

Timolol

Intervention Type DRUG

1 drop of timolol was given to study eye after washout period of 1 week between drugs

dorzolamide

solution, 1 drop of 20 mg/ml dorzolamide, was given to study eye after washout period of 1 week between drugs

Group Type EXPERIMENTAL

Dorzolamide

Intervention Type DRUG

1 drop of dorzolamide was given to study eye after washout period of 1 week between drugs

Other

no drug given and pupil measurements were performed before and at 30 and 180 min at equivalent hours as drugs measurements

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Latanoprost

1 drop of latanoprost was given to study eye after washout period of 1 week between drugs

Intervention Type DRUG

Timolol

1 drop of timolol was given to study eye after washout period of 1 week between drugs

Intervention Type DRUG

Dorzolamide

1 drop of dorzolamide was given to study eye after washout period of 1 week between drugs

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Optimol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy subjects

Exclusion Criteria

* ophthalmological diseases
* systemic disease
* smoking
* refractive error \>= 6 diopters
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Glostrup University Hospital, Copenhagen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Birgit Sander

md

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Henrik Lund-Andersen, Professor

Role: STUDY_DIRECTOR

Head of the project

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Glostrup University Hospital

Glostrup Municipality, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GlostrupUH

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Comparison of Latanoprost Vs. Timolol
NCT00579969 TERMINATED PHASE2
Patient Preference Study
NCT00576342 COMPLETED PHASE3
Cosopt Versus Xalatan
NCT00273429 COMPLETED PHASE4